In this Q&A, Mathioudaki discusses the post-hoc FLAME trial, which links ICS and LAMA discontinuation to transient exacerbation risk in COPD.
Alexander Mathioudakis, MD, PhD
Advertisement
Alexander Mathioudakis, MD, PhD, from the biology department at The University of Manchester.
Articles by Alexander Mathioudakis, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Long-Acting Growth Hormone Analogs: Beyond Convenience to Individualized Care
2
All 12 Tegoprubart Recipients Off External Insulin Following Islet Implant in Pilot Study
3
The HCPFive: Top News for Healthcare Providers from the Week of 07/05
4
Real-World Registries vs Clinical Trials in Long-Acting Growth Hormone Therapy
5